A Study Of Ranpirnase(Onconase®) To Pemetrexed Plus Carboplatin In Patients With Non-Squamous Non-Small Cell Lung Cancer
| Status: | Withdrawn |
|---|---|
| Conditions: | Lung Cancer, Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/21/2016 |
A Phase II Trial of Addition of Ranpirnase(ONCONASE®) to Permetrexed Plus Carboplatin in Patientes With Non-Squamous Non-Small Cell Lung Cancer
The purpose of the trial is to determine the rate of improvement in objective tumor
response, following the addition of ranpirnase to ongoing pemetrexed—carboplatin
chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.
response, following the addition of ranpirnase to ongoing pemetrexed—carboplatin
chemotherapy, for patients with SD or PR following 2 cycles of doublet chemotherapy.
Inclusion Criteria:
- Age greater than 18 years
- ECOG less than 2
- Estimated survival of greater than 12 weeks
Exclusion Criteria:
- Prior systemic chemotherapy for locally advanced or metastatic NSCLC
- Use of any investigational agent within 28 days prior to registration
- Known hypersensitivity to any of the study drugs
- Brain metastases or leptomeningeal disease
- History of prior malignancy within the past three years
We found this trial at
6
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials